Anavex Life Sciences Corp (AVXL)

[falconer66a]

Makes no sense to us, but....

Why would you introduce a new drug to compete directly with the one you are trying to approved?

A puzzle, indeed. But sooner or later the reasons Anavex has advanced its particular drug candidates in the sequence we see (Anavex 2-73, blarcamesine first, for three central nervous system diseases; followed by Anavex 3-71, first for frontotemporal disease; perhaps others to come) will become known.

None of this is the random tossing of drug candidate mud against the barn, merely to see what might stick. Dr. Missling owns a gigantic number of AVXL shares. He's smart; has earned a number of higher degrees. He and his associates have a well-considered plan, that over five to ten years will play out profitably for all but the company's pharmaceutical competitors.